Differential up-regulation of Vesl-1/Homer 1 protein isoforms associated with decline in visual performance in a preclinical glaucoma model

Biochemistry, Genetics and Molecular Biology

• Protein Isoform 100%
• Upregulation 100%
• DBA 2 Mouse 100%
• Vision 100%
• Genetics 50%
• Isoform 50%
• Immunoreactivity 50%
• Retinal Ganglion Cell 50%
• Gene Product 50%
• Scaffold Protein 50%
• Spontaneous Mutation 50%
• Cell Loss 50%
• Immediate Early Gene 50%
• Visual Field 50%
• Drug Therapy 50%

Keyphrases

• Protein Isoforms 100%
• Hybrid Optimization Model for Electric Renewables (HOMER) 100%
• Visual Performance 100%
• Retina 71%
• Glaucoma 42%
• Glaucomatous 28%
• Homer Proteins 28%
• Treatment Strategy 14%
• Blindness 14%
• Differentially Expressed 14%
• Gene Products 14%
• Clinical Parameters 14%
• Disease Progression 14%
• Protein Level 14%
• Ca2+ 14%
• Immunoreactivity 14%
• Disease Severity 14%
• Vision Loss 14%
• Synaptic 14%
• Severe Disease 14%
• Therapeutic Target 14%
• Ocular Pathology 14%
• Targets for Therapy 14%
• Surgical Treatment 14%
• Synaptic Proteins 14%
• Spontaneous mutation 14%
• Scaffold Protein 14%
• Neurodegenerative 14%
• Disease Phenotype 14%
• Visual Field Defect 14%
• Therapy Development 14%
• Optic Nerve 14%
• Synaptic Function 14%
• Comprehensive Treatment 14%
• Retinal Ganglion Cell Loss 14%
• Intracellular Ca2+ Release 14%
• Immediate-early Gene 14%

Neuroscience

• Glaucoma 100%
• Isoprotein 100%
• Homer Scaffolding Protein 28%
• Retinal Ganglion Cell 14%
• Optic Nerve 14%
• Gene Product 14%
• Cell Loss 14%
• Scaffold Protein 14%
• Immediate Early Gene 14%
• Drug Therapy 14%